Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Amicus Therapeutics (FOLD) over the last 10 years, with Q3 2025 value amounting to -$1.2 million.

  • Amicus Therapeutics' Exchange Rate Effect rose 7613.37% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year increase of 25133.1%. This contributed to the annual value of -$4.0 million for FY2024, which is 16386.25% down from last year.
  • Per Amicus Therapeutics' latest filing, its Exchange Rate Effect stood at -$1.2 million for Q3 2025, which was up 7613.37% from $10.0 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Exchange Rate Effect peaked at $18.5 million during Q4 2022, and registered a low of -$20.7 million during Q3 2022.
  • Over the past 5 years, Amicus Therapeutics' median Exchange Rate Effect value was -$1.2 million (recorded in 2021), while the average stood at -$199000.0.
  • Per our database at Business Quant, Amicus Therapeutics' Exchange Rate Effect plummeted by 307657.34% in 2022 and then surged by 349693.88% in 2025.
  • Over the past 5 years, Amicus Therapeutics' Exchange Rate Effect (Quarter) stood at -$908000.0 in 2021, then soared by 2137.56% to $18.5 million in 2022, then crashed by 121.11% to -$3.9 million in 2023, then soared by 179.54% to $3.1 million in 2024, then plummeted by 138.62% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, $10.0 million for Q2 2025, and $4.8 million during Q1 2025.